Ariad Pharmaceuticals Exec: We have not yet had a meeting with the FDA to discuss suspension of Iclusig (ponatinib) marketing, we do not yet know what the FDA wants - conf call comments - Asked if new trials are needed to get Iclusig back on market, executives note they are not sure, can't rule it out, option has not been requested by FDA `yet.